Make an application to the InhibOx/NFCR virtual screening service
Make DrugFinder Application
The website of our FP6 consortiumDeZnIT Go to DeZnIT website
InhibOx works closely with MolPort
MolPort

Welcome to Inhibox

The company's primary objective is to develop novel and effective computational methods for drug discovery in order to improve the productivity of lead and candidate identification.

InhibOx was founded in 2001 by Professor W. Graham Richards, chairman of Chemistry at the University of Oxford and world leading computational chemist. The company grew from the outstandingly successful screen saver project which involved some 3.5 million personal computers in over 200 countries: the world's biggest computational chemistry experiment finding lead compounds to inhibit cancer targets, anthrax and smallpox. Subsequently, the company has built up a significant technology platform. Its main ongoing research activities comprise the development of entirely novel computational discovery methods and associated with this, the development of Scopius a very large database of chemical structures.

DrugFinder

News

InhibOx and the National Foundation for Cancer Research announce the launch of DrugFinder, a free hit identification service. more...

Dr. Garrett M. Morris joins InhibOx. more...

Biochemical Institute, University of Kiel joins EU DeZnIT consortium. more...

European Union supports €3M project to develop technology against a major therapeutically relevant enzyme family. more...

older news...